Use of umbilical cord mesenchymal stem cell-derived small extracellular vesicles in preparation of drug for treating type 2 diabetes

By using umbilical cord mesenchymal stem cell-derived small extracellular vesicles (hucMSC-sEV), the problem that the existing technology cannot maintain and restore β-cell function is solved, reducing blood sugar and improving insulin sensitivity, reversing β-cell apoptosis and Dedifferentiation significantly improves the quality of pancreatic β cells.

WO2024234471A1PCT designated stage expired Publication Date: 2024-11-21JIANGSU UNIV
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2023/107208
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-17
Filing Date
2023-07-13
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

The existing treatment methods for type 2 diabetes cannot effectively maintain and restore β-cell function, resulting in insulin resistance and hyperglycemia, lack of maintenance methods for endogenous β-cell volumes, and it is urgently necessary to develop new drugs to improve β-cell function.

Method used

Umbilical cord mesenchymal stem cell-derived small extracellular vesicles (hucMSC-sEV) were used as a therapeutic drug, extracted and injected in the tail vein by differential centrifugation, which was used to reduce blood sugar, enhance pancreatic β-cell function, reverse β-cell apoptosis and deletion. Differentiation to improve the quality of pancreatic β cells.

Benefits of technology

hucMSC-sEV can effectively reduce blood sugar, improve glucose tolerance, increase islet volume and β-cell number, reverse β-cell apoptosis and dedifferentiation, significantly improve islet function, and provide a safe and effective new therapeutic strategy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2023107208_21112024_PF_FP_ABST
    Figure CN2023107208_21112024_PF_FP_ABST
Patent Text Reader

Abstract

A use of umbilical cord mesenchymal stem cell-derived small extracellular vesicles (hucMSC-sEVs) in preparation of a drug for treating type 2 diabetes. Experiments prove that hucMSC-sEVs can effectively reduce the blood glucose of a db / db mouse model, mitigate the pancreatic islet morphology disorder, increase the number of β cells, and remodel pancreatic β cells by reversing β cell apoptosis and dedifferentiation. Hence, hucMSC-sEVs can effectively improve the structure and function of pancreatic islets, reduce the blood glucose level caused by type 2 diabetes, regulate glucose homeostasis, and improve the quality of pancreatic β cells, can be used as a novel drug for treating type 2 diabetes, and is beneficial to clinical popularization and application.
Need to check novelty before this filing date? Find Prior Art

Description

Application of umbilical cord mesenchymal stem cell-derived small extracellular vesicles in the preparation of drugs for the treatment of type 2 diabetes

[0001] This application claims priority to a Chinese patent application filed with the Patent Office of China on May 17, 2023, with application number 202310554417.1 and invention name “Application of small extracellular vesicles derived from umbilical cord mesenchymal stem cells in the preparation of drugs for the treatment of type 2 diabetes”, the entire contents of which are incorporated by reference into this application. Technical Field

[0002] The present invention belongs to the field of biomedicine technology, and specifically relates to the application of umbilical cord mesenchymal stem cell-derived small extracellular vesicles in improving pancreatic islet function in a type 2 diabetes model. Background Art

[0003] Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease characterized by hyperglycemia caused by insulin resistance and relative insulin deficiency. As insulin resistance increases, β-cells initially compensate by increasing insulin production and synthesis and increasing β-cell proliferation. Long-term insulin resistance and inflammation can lead to β-cell stress and compensation. Sustained hyperglycemia and hyperlipidemia can cause β-cell glucolipid toxicity and β-cell failure, leading to dedifferentiation and / or β-cell death, a decrease in functional β-cell mass, and type 2 diabetes. As diabetes progresses, chronic damage to multiple organs, including blood vessels, kidneys, eyes, and feet, can occur. The high disability and mortality rates associated with diabetic complications place a heavy burden on patients and their families. Therefore, research into effective prevention and treatment of type 2 diabetes is highly beneficial.

[0004] The mainstays of treatment for T2DM currently include a balanced diet, moderate exercise, and oral hypoglycemic medications. Commonly used hypoglycemic drugs primarily enhance peripheral insulin sensitivity (e.g., thiazolidinediones), inhibit hepatic gluconeogenesis (e.g., biguanides), and increase insulin secretion in a glucose-dependent manner (e.g., glucagon-like). These drugs are intended only to alleviate symptoms, specifically by enhancing insulin secretion from remaining β cells and improving insulin sensitivity in T2DM, as well as normalizing blood glucose through strictly controlled exogenous insulin therapy. Although even a small amount of preserved endogenous insulin secretion has been shown to have significant clinical benefits, commonly used antidiabetic therapies do not target the maintenance of endogenous β-cell mass. Therefore, the development of new, safe, and effective drugs for restoring β cells and improving β-cell function is urgently needed.

[0005] Summary of the Invention

[0006] In view of this, the purpose of the present invention is to provide a use of human umbilical cord mesenchymal stem cell derived small extracellular vesicles (hucMSC-sEV) in the preparation of a drug for the treatment of type 2 diabetes, thereby lowering blood sugar, enhancing pancreatic β-cell function, improving pancreatic morphological disorders, reversing β-cell apoptosis and dedifferentiation, and improving pancreatic β-cell quality.

[0007] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0008] The present invention provides an application of umbilical cord mesenchymal stem cell-derived small extracellular vesicles in the preparation of a drug for treating type 2 diabetes.

[0009] Preferably, the method for preparing the umbilical cord mesenchymal stem cell-derived small extracellular vesicles comprises: culturing human umbilical cord mesenchymal stem cells to 70%-80% confluence, culturing in MEM-α medium for 40-50 hours, collecting the culture supernatant, and obtaining the precipitate by differential centrifugation, which is the umbilical cord mesenchymal stem cell-derived small extracellular vesicles.

[0010] More preferably, the differential centrifugation method comprises: centrifuging the supernatant at 250-350 g, 1500-2500 g, 9000-11000 g, 1500-2500 g, and 98000-120000 g, in sequence.

[0011] Preferably, the umbilical cord mesenchymal stem cell-derived small extracellular vesicles are injected through the tail vein; the injection dose is 8-13 mg / kg.

[0012] Preferably, the umbilical cord mesenchymal stem cell-derived small extracellular vesicles can lower blood sugar.

[0013] Preferably, the umbilical cord mesenchymal stem cell-derived small extracellular vesicles can improve glucose tolerance.

[0014] Preferably, the umbilical cord mesenchymal stem cell-derived small extracellular vesicles can increase the volume of pancreatic islets and the number of β cells.

[0015] Preferably, the umbilical cord mesenchymal stem cell-derived small extracellular vesicles can reverse β-cell apoptosis and dedifferentiation.

[0016] Preferably, the drug further comprises a pharmaceutically acceptable carrier.

[0017] Compared with the prior art, the present invention has the following beneficial effects:

[0018] The present invention provides a new use of hucMSC-sEV for the treatment of type 2 diabetes. Compared with conventional cell therapy, hucMSC-sEV, as a non-cellular therapy, has the advantages of simple material collection, convenient operation, low immunogenicity, and the ability to continuously and effectively lower blood sugar while increasing the mass of pancreatic β cells, greatly reducing side effects, which is conducive to clinical promotion and application and provides a new strategy for the treatment of patients with chronic diseases.

[0019] The present invention experimentally verified that hucMSC-sEV can effectively lower blood sugar and reduce mouse weight in the db / db mouse model. HE staining, Western Blot, immunofluorescence detection and qRT-PCR staining methods also verified that hucMSC-sEV can effectively reverse mouse pancreatic β-cell apoptosis and dedifferentiation in type 2 diabetes, increase β-cell number, and improve pancreatic islet function. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 shows the morphology of exosomes observed by electron microscopy (TEM) of hucMSC-sEV in Example 1;

[0021] FIG2 is the NTA particle size detection result of hucMSC-sEV in Example 1;

[0022] FIG3 is the result of WB method detection of the expression of surface characteristic markers of hucMSC-sEV in Example;

[0023] FIG4 shows the blood glucose levels of mice in each group in Example 2;

[0024] FIG5 shows the body weight of mice in each group in Example 2;

[0025] FIG6 shows the blood glucose levels of mice in each group tested using the IPGTT method in Example 2;

[0026] FIG7 shows fasting insulin levels of mice in each group in Example 2 detected using the HOMA-β method;

[0027] FIG8 is the in vivo imaging results of mice in each group in Example 2;

[0028] FIG9 is the HE staining results of pancreatic tissue of mice in each group in Example 2;

[0029] FIG10 shows the pancreas volume of each group of mice in Example 2 detected by tissue immunofluorescence;

[0030] FIG11 shows the expression of mature β-cell transcription factors Pdx1, FoxO1, Oct4, and Nanog in each group of mice in Example 2 detected by tissue immunofluorescence;

[0031] Figure 12 shows the expression levels of PCNA, Bcl-2, Bax, and cleaved capase3 molecular markers in pancreatic tissue of each group of mice in Example 2 detected by Western Blot method;

[0032] FIG13 shows the expression levels of mature β-cell markers Pdx1, FoxO1, and Nkx6.1 in pancreatic tissue of mice in each group in Example 2 detected by qRT-PCR;

[0033] Figure 14 is the Western Blot method to detect the expression levels of PCNA, Bcl-2, and Bax molecular markers in each group of cells in Example 3;

[0034] FIG15 is a graph showing the expression levels of Pdx1 and FoxO1 molecular markers in cells of each group in Example 3 detected by Western Blot;

[0035] FIG16 is a graph showing the expression levels of Oct4 and Nanog molecular markers in cells of each group in Example 3 detected by Western Blot method;

[0036] FIG17 shows the expression levels of PCNA, Bcl-2, Bax, Pdx1, and FoxO1 molecular markers in cells of each group in Example 3 detected by cell immunofluorescence method. DETAILED DESCRIPTION

[0037] The present invention provides an application of umbilical cord mesenchymal stem cell-derived small extracellular vesicles in the preparation of a drug for treating type 2 diabetes.

[0038] The preparation method of hucMSC-sEV of the present invention preferably comprises: culturing human umbilical cord mesenchymal stem cells to 70%-80% confluence, culturing in MEM-α medium for 40-50 hours, collecting the culture supernatant, and obtaining the precipitate by differential centrifugation as the hucMSC-sEV; the culture time in MEM-α medium is more preferably 48 hours; the differential centrifugation method preferably comprises: centrifuging the supernatant at 250-350g, 1500-2500g, 9000-11000g, and 10000-20000g, respectively. The centrifugation is carried out at 1500-2500g, 98000-120000g, and the centrifugation time is 8-12min, 15-25min, 25-35min, 25-35min, 25-35min, respectively; more preferably, the centrifugation is carried out at 300g, 2000g, 10000g, 2000g, 10000g, and the more preferred centrifugation time is 10min, 20min, 30min, 30min, 30min, respectively; the centrifugation temperature is preferably 2-6°C, more preferably 4°C.

[0039] In the present invention, the hucMSC-sEV is preferably injected through the tail vein; the injection dose is preferably 8-13 mg / kg, more preferably 10 mg / kg; the hucMSC-sEV can lower blood sugar; the hucMSC-sEV can improve glucose tolerance; the hucMSC-sEV can increase the volume of pancreatic islets and the number of β cells. The present invention conducted animal experiments, and by monitoring the blood glucose and weight of each group of mice, it was found that the hucMSC-sEV of the present invention effectively reduced the blood glucose and weight of db / db mice; by detecting the blood glucose of each group of fasting mice by IPGTT, it was found that the hucMSC-sEV of the present invention effectively improved the glucose tolerance of db / db mice; by detecting the fasting insulin levels of each group of fasting mice by HOMA-β, it was found that the pancreatic β cell function of the hucMSC-sEV mice of the present invention was significantly improved; by detecting the pancreatic islets of each group of mice by HE staining, it was found that the hucMSC-sEV of the present invention can significantly increase the number of pancreatic islets, increase the volume of pancreatic islets, and improve the disorder of pancreatic islet structure; by tissue immunofluorescence detection of pancreatic tissue sections of each group of mice, it was found that the hucMSC-sEV of the present invention effectively increased β cells and reversed β cell dedifferentiation; by tissue protein extraction and Western Blot detection of pancreatic tissue of each group of mice, it was found that the hucMSC-sEV of the present invention effectively reversed the apoptosis of pancreatic β cells in mice.

[0040] In the present invention, the hucMSC-sEV can reverse β-cell apoptosis and dedifferentiation. Cell experiments conducted by the present invention revealed that the hucMSC-sEV effectively reversed apoptosis and dedifferentiation of INS-1 cells in a high-glucose environment through cell protein extraction and Western Blot analysis. Cell immunofluorescence assays also revealed that the hucMSC-sEV effectively promoted cell proliferation and reversed apoptosis and dedifferentiation in a high-glucose environment.

[0041] In the present invention, the drug preferably further includes a pharmaceutically acceptable carrier; the active ingredient is hucMSC-sEV, and the content of the active ingredient is preferably 0.1-99%; the carrier preferably includes a diluent, stabilizer, or excipient; and the drug is preferably in the form of an injection. The drug of the present invention can be administered intraperitoneally, subcutaneously, intramuscularly, intravenously, or nasally.

[0042] The technical solutions provided by the present invention are described in detail below with reference to the embodiments, but they should not be construed as limiting the scope of protection of the present invention.

[0043] Example 1

[0044] Extraction of hucMSC-sEVs

[0045] 1. Isolation and purification of human umbilical cord mesenchymal stem cells (hucMSC)

[0046] (1) After obtaining the consent of the mother herself, collect fresh umbilical cords from full-term women who have undergone cesarean section and have normal development, and exclude infectious diseases such as AIDS, syphilis, and hepatitis B;

[0047] (2) After washing the surface blood with PBS and removing the arteries, veins, and vascular endothelium, the umbilical cord was transferred to a large dish containing MEM-α medium with 15% fetal bovine serum. The umbilical cord was cut into small square pieces with a side length of approximately 2 mm using scissors and transferred to a large dish containing MEM-α medium for adherent growth.

[0048] (3) Culture in a carbon dioxide incubator at 37°C and 5% CO2, and change the medium every 3 days. After 10 days, when the primary cells around the meat pieces appear fibrous and have a high degree of fusion, digest and passage them, and select the third-generation cells for the experiment.

[0049] (4) Culture mesenchymal stem cells in a carbon dioxide incubator at 37°C and 5% CO2 until the cells are 70%-80% confluent, discard the supernatant, rinse twice with PBS, and switch to a specific MEM-α medium for 48 hours until the cells are fully confluent, and collect the culture supernatant.

[0050] 2. Isolation of hucMSC-sEVs

[0051] (1) The collected supernatant was centrifuged at 300 × g for 10 min to remove intact cells;

[0052] (2) The cells were centrifuged at 2000 × g for 20 min to further remove dead cells and cell debris;

[0053] (3) Transfer the supernatant to a 10,000 g centrifuge tube and balance it. Centrifuge at 10,000 g for 30 min at 4°C to remove impurities such as organelles.

[0054] (4) Transfer the upper layer of liquid to a 100KD ultrafiltration tube, centrifuge at 2000g for 30 min at 4°C, concentrate the supernatant, draw the bottom concentrate, and repeatedly concentrate until there is no residual liquid in the upper layer;

[0055] (5) The concentrated supernatant was ultracentrifuged at 100,000 g at 4°C, the upper liquid was discarded, and an appropriate amount of PBS was added to dissolve the bottom precipitate. After sterilization with a 0.22 μm filter membrane, the hucMSC-sEV protein concentration was detected by the BCA method and stored at -80°C.

[0056] 3. Identification of hucMSC-sEVs

[0057] The morphology of the extracted hucMSC-sEVs was observed by scanning electron microscopy (TEM). As shown in Figure 1 , the extracted hucMSC-sEVs were in a typical vesicle shape.

[0058] The particle size was detected by NTA. The results are shown in FIG2 . The particle size of the hucMSC-sEV was about 150 nm.

[0059] The surface characteristic markers of hucMSC-sEV were detected by WB method. The results are shown in Figure 3. The extracted hucMSC-sEV expressed surface characteristic markers such as CD9, CD63 and TSG101, but did not express calnexin.

[0060] As can be seen from Figures 1-3, the hucMSC-sEV extracted by the present invention conforms to the biological characteristics of small extracellular vesicles.

[0061] Example 2

[0062] Application of hucMSC-sEV in the db / db mouse model

[0063] 1. Construction of db / db type 2 diabetes mouse model

[0064] The db / db mouse model was constructed and the drug administration was as follows:

[0065] Fifteen 4-week-old db / m and db / db mice were randomly divided into three groups: (1) db / m group (2) db / db group (3) db / db group + hucMSC-sEV group of Example 1, with 5 mice in each group. They were fed normally and adaptively until 8 weeks of age. After db / db mice spontaneously developed hyperglycemia, the mice in the treatment group were injected with hucMSC-sEV (10 mg / kg / 3 days) through the tail vein. The mice were killed 4 weeks later for in vivo histological analysis.

[0066] 2. Effect identification

[0067] Blood glucose and body weight monitoring methods: Blood glucose and body weight were monitored in mice during the 8-12 week treatment period. The mice were fasted for 12 hours the day before measurement, and blood was collected from the tail vein the next morning for measurement using a Roche blood glucose meter. The results, shown in Figures 4 and 5, indicate that the hucMSC-sEV of the present invention effectively reduced blood glucose and body weight in db / db mice.

[0068] IPGTT assay: After fasting for 16 hours, mice were intraperitoneally injected with glucose (2 g / kg bw). Blood glucose was measured at 0, 15, 30, 60, 90, and 120 min after injection. The results are shown in Figure 6 , indicating that the hucMSC-sEV of the present invention effectively improved glucose tolerance in db / db mice.

[0069] HOMA-β assay: Mice were fasted for 12 hours the day before measurement, and fasting blood glucose and fasting insulin levels were measured. HOMA-β was calculated using the following formula: HOMA-β = [20 x fasting insulin level (mU / l)] / [fasting blood glucose (mmol / l) - 3.5]. The results, shown in Figure 7, demonstrate that pancreatic β-cell function in mice was significantly improved after hucMSC-sEV treatment.

[0070] Small animal in vivo imaging detection method: hucMSC-sEV labeled with DIR dye was injected through the tail vein, and the labeled hucMSC-sEV was traced using a small animal in vivo imaging instrument. The results are shown in Figure 8, indicating that the hucMSC-sEV of the present invention can be taken up by major organs, among which the liver, pancreas, and spleen tissues are richly expressed.

[0071] HE staining: Isolated pancreatic tissue was fixed overnight with 4% formaldehyde, embedded in paraffin, and prepared into 4 μm sections. The sections were stained with H&E and observed under a microscope (Nikon, Tokyo, Japan). The results, shown in Figure 9, demonstrate a significant increase in the number and size of pancreatic islets in the pancreatic tissue of mice treated with hucMSC-sEVs, as well as improvement in islet structural disorder.

[0072] Tissue immunofluorescence detection method: 4μm-thick paraffin-embedded mouse pancreatic tissue sections were oven-baked at 70°C for 2 hours, dewaxed, and then placed in 0.01M citrate buffer, boiled in a steamer for 30 minutes, and allowed to cool naturally. The sections were blocked with 5% bovine serum albumin (BSA) for 1 hour, incubated with the specific primary antibody insulin overnight at 4°C, and then incubated with specific primary antibodies (glucagon, Pdx1, FoxO1, Oct4, Nanog) at 4°C overnight. Specific fluorescent secondary antibodies were incubated at 37°C in the dark for 1 hour, and cell nuclei were visualized using DAPI. Sections were observed and images were acquired using a laser confocal microscope. The results are shown in Figures 10 and 11.

[0073] As shown in Figure 10, the islet volume in the pancreatic tissue sections of db / db mice was reduced and the number of insulin-positive β cells decreased, but after hucMSC-sEV treatment, the islet volume increased and the number of insulin-positive β cells increased significantly, indicating that hucMSC-sEV treatment effectively increased β cells.

[0074] As shown in Figure 11, the number of β cells co-expressing mature β cell transcription factors Pdx1 and FoxO1 in pancreatic tissue sections of db / db mice decreased, while the number of β cells co-expressing pluripotency markers Oct4 and Nanog increased. After hucMSC-sEV treatment, the number of β cells co-expressing Pdx1 and FoxO1 in pancreatic tissue sections of mice increased, while the number of β cells co-expressing Oct4 and Nanog decreased, indicating that hucMSC-sEV reversed β cell dedifferentiation.

[0075] Tissue protein extraction and Western Blot detection method: 1 cm3 small pieces of freshly extracted pancreatic tissue were taken, minced with scissors, washed with PBS and centrifuged at 3000g for 5 min to remove blood, then lysed with RIPA buffer containing phosphatase inhibitors and protease inhibitors, ultrasonically disrupted, and then centrifuged at 12000g for 10 min. The supernatant was aspirated to obtain the total tissue protein, and an equal volume of Loading Buffer was added and boiled for 10 min. After the protein concentration was determined by BCA method, 20 μg of protein in each group was separated by polyacrylamide gel electrophoresis, transferred to PVDF membrane, and blocked with TBST containing 5% skim milk for 60 min. Then, the membrane was incubated with specific primary antibodies (PCNA, Bcl-2, Bax, cleaved capase3) at 4°C overnight, and incubated with specific mouse or rabbit secondary antibodies at 37°C for 1 h. The results are shown in Figure 12.

[0076] As shown in Figure 12, the expression of proliferation markers such as PCNA and Bcl-2 in the pancreatic tissue of db / db mice was weakened, and the expression of apoptosis markers such as Bax and cleaved capase3 was increased. However, after hucMSC-sEV treatment, the expression level of proliferation markers in the pancreatic tissue proteins of mice increased, and the expression level of apoptosis markers decreased, indicating that hucMSC-sEV effectively reversed the apoptosis of pancreatic β cells in mice.

[0077] Tissue RNA extraction, reverse transcription, and qRT-PCR assays: Pancreatic tissue was minced to the size of a grain of rice. RNA was extracted using an organic solvent such as Trizol. RNA concentration was determined using a Nanodrop instrument and ND-1000 software. cDNA was synthesized using a Vazyme reverse transcription kit, and qRT-PCR was performed using a SYBR Green PCR kit. The results are shown in Figure 13.

[0078] As shown in Figure 13, the expression of mature β-cell markers such as Pdx1, FoxO1, and Nkx6.1 in mice treated with hucMSC-sEV was significantly increased.

[0079] Example 3

[0080] Application of hucMSC-sEV in pancreatic islet cell model

[0081] Rat pancreatic islet cell carcinoma cells (INS-1) were purchased from the Cell Bank of the Chinese Academy of Sciences and cultured in RPMI-1640 (Bioind) medium containing L-glutamine (Thermo Fisher Scientific, USA), 10% fetal bovine serum (FBS, Gibco, Germany), 50 μmol / L β-mercaptoethanol (Procell), and 1% penicillin-streptomycin under standard culture conditions (37°C, 5% CO2).

[0082] The cells were divided into three groups: (1) Control group (2) HG group: cultured with RPMI-1640 containing 33.3mmoL glucose (3) HG+hucMSC-sEV group. Cell treatment method: INS-1 cells were cultured at 2×10 5 Density was seeded into 6-well plates, and INS-1 cells were treated with 33.3 mmol high-glucose RPMI-1640 medium for 48 h to simulate the diabetic environment. After inducing high-glucose damage, hucMSC-sEV (particle number 1×10 7 / 30μL) for 24h.

[0083] Cell protein extraction and Western Blot analysis: Cells were lysed using RIPA buffer containing phosphatase and protease inhibitors, mixed on a vortex for 5 minutes, and placed on ice for 10 minutes. After five cycles, the cells were centrifuged at 12,000 g for 10 minutes. The supernatant was aspirated as the total cellular protein. After adding an equal volume of loading buffer, the protein concentration was determined by the BCA assay. The Western Blot procedure was the same as for tissue protein. The cells were then incubated with specific primary antibodies (PCNA, Bcl-2, Bax, Pdx1, FoxO1, Oct4, Nanog) at 4°C overnight, followed by incubation with specific mouse or rabbit secondary antibodies at 37°C for 1 hour. Specific results are shown in Figures 14, 15, and 16.

[0084] As shown in Figure 14, after hucMSC-sEV treatment, the expression of PCNA and Bcl-2 in INS-1 cells in a high glucose environment increased, the cell proliferation ability was enhanced, the expression of Bax and other proteins decreased, and apoptosis was weakened; as shown in Figure 15, the expression of β-cell maturation markers such as Pdx1 and FoxO1 increased; as shown in Figure 16, the expression of dedifferentiation markers Oct4 and Nanog decreased, indicating that hucMSC-sEV effectively reversed the apoptosis and dedifferentiation of INS-1 cells in a high glucose environment.

[0085] Cell immunofluorescence detection method: The same number of cells were seeded in a 12-well plate with cell slides, and each group was given the above-mentioned different treatments. After the cells grew for 72 hours, the cell slides were removed, washed 3 times with PBS, fixed with paraformaldehyde for 30 minutes, permeabilized with 0.1% Triton-X100 for 10 minutes, blocked with BSA for 30 minutes, and incubated with specific primary antibodies (PCNA, Bcl-2, Bax, Pdx1, FoxO1, Oct4, Nanog) at 4°C overnight, incubated with specific fluorescent secondary antibodies at 37°C for 1 hour, and Hoechst 33,342 was used to observe the cell nucleus. The results are shown in Figure 17.

[0086] As shown in Figure 17 , after hucMSC-sEV treatment, the expression of PCNA and Bcl-2 in INS-1 cells increased, the expression of Bax decreased, and the expression of Pdx1 and FoxO1 increased, indicating that hucMSC-sEV effectively promoted cell proliferation in a high-glucose environment and reversed apoptosis and dedifferentiation.

[0087] In summary, the hucMSC-sEV provided by the present invention can lower blood sugar in the db / db mouse model, enhance pancreatic β-cell function, improve pancreatic morphological disorder, reverse β-cell apoptosis and dedifferentiation, and improve pancreatic β-cell quality.

[0088] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as within the scope of protection of the present invention.

Claims

1. Application of small extracellular vesicles derived from umbilical cord mesenchymal stem cells in the preparation of drugs for the treatment of type 2 diabetes.

2. The use according to claim 1, characterized in that: The preparation method of the umbilical cord mesenchymal stem cell-derived small extracellular vesicles comprises: culturing human umbilical cord mesenchymal stem cells to 70%-80% confluence, culturing in MEM-α culture medium for 40-50 hours, collecting the culture medium supernatant, and obtaining the precipitate by differential centrifugation, which is the umbilical cord mesenchymal stem cell-derived small extracellular vesicles.

3. The use according to claim 2, characterized in that: The differential centrifugation method comprises: centrifuging the supernatant at 250-350g, 1500-2500g, 9000-11000g, 1500-2500g, and 98000-120000g in sequence.

4. The use according to claim 1, characterized in that: The umbilical cord mesenchymal stem cell-derived small extracellular vesicles are injected through the tail vein; the injection dose is 8-13 mg / kg.

5. The use according to claim 1, characterized in that: The umbilical cord mesenchymal stem cell-derived small extracellular vesicles can lower blood sugar.

6. The use according to claim 1, characterized in that: The umbilical cord mesenchymal stem cell-derived small extracellular vesicles can improve glucose tolerance.

7. The use according to claim 1, characterized in that: The umbilical cord mesenchymal stem cell-derived small extracellular vesicles can increase the volume of pancreatic islets and the number of β cells.

8. The use according to claim 1, characterized in that: The umbilical cord mesenchymal stem cell-derived small extracellular vesicles can reverse β-cell apoptosis and dedifferentiation.

9. The use according to any one of claims 1 to 8, characterized in that: The medicament further includes a pharmaceutically acceptable carrier.

Citation Information

Patent Citations

  • Separation and purification method of human umbilical cord mesenchymal stem cell exosome and application of human umbilical cord mesenchymal stem cell exosome

    CN108103017A

  • Mesenchymal stem cell exosome for reversing type 2 diabetes mellitus islet beta cell dedifferentiation as well as preparation method and application of mesenchymal stem cell exosome

    CN113215094A

  • Application of umbilical cord mesenchymal stem cell-derived exosome in preparation of insulin sensitizer

    CN115896031A

  • NMN functionalized umbilical cord mesenchymal stem cell-derived small extracellular vesicle as well as preparation method and application thereof

    CN115919899A